NYSEAMERICAN:CVM Cel-Sci (CVM) Stock Price, News & Analysis $1.49 +0.01 (+0.68%) Closing price 04:10 PM EasternExtended Trading$1.49 +0.00 (+0.27%) As of 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Cel-Sci Stock (NYSEAMERICAN:CVM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cel-Sci alerts:Sign Up Key Stats Today's Range$1.43▼$1.5150-Day Range$1.19▼$4.9552-Week Range$0.89▼$13.48Volume177,759 shsAverage Volume229,047 shsMarket Capitalization$12.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates. The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells. Multikine has been evaluated in a pivotal Phase III clinical trial, and CEL-SCI has conducted additional clinical studies and manufacturing development to support potential registration in the United States and abroad. Beyond Multikine, the company is advancing early-stage programs in infectious disease and oncology that leverage its expertise in immune modulation. CEL-SCI has carried out clinical trials and manufacturing activities in multiple regions, including North America, Europe, Latin America and South Africa. Its research and development operations encompass in-house laboratories in Virginia and collaborations with contract research organizations around the world. This global footprint reflects the company’s commitment to rigorous clinical testing and regulatory engagement in key markets. Under the leadership of President and Chief Executive Officer Geert Kersten, CEL-SCI maintains a small executive team supported by a board of directors with expertise in biotechnology, clinical operations and regulatory affairs. The company’s scientific staff comprises immunologists, process development specialists and clinical trial managers who collectively steer CEL-SCI’s programs from preclinical research through late-stage development. AI Generated. May Contain Errors. Read More Cel-Sci Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreCVM MarketRank™: Cel-Sci scored higher than 37% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cel-Sci. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cel-Sci is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cel-Sci is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCel-Sci has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.33% of the float of Cel-Sci has been sold short.Short Interest Ratio / Days to CoverCel-Sci has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cel-Sci has recently decreased by 64.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCel-Sci does not currently pay a dividend.Dividend GrowthCel-Sci does not have a long track record of dividend growth. News and Social Media3.8 / 5News SentimentN/A News SentimentCel-Sci has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cel-Sci this week, compared to 0 articles on an average week.Search Interest5 people have searched for CVM on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cel-Sci to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cel-Sci insiders have not sold or bought any company stock.Percentage Held by Insiders14.06% of the stock of Cel-Sci is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.08% of the stock of Cel-Sci is held by institutions.Read more about Cel-Sci's insider trading history. Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cel-Sci and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVM Stock News HeadlinesCEL-SCI Reports Fiscal Second Quarter 2026 ResultsMay 18, 2026 | finance.yahoo.comCEL-SCI Reports Fiscal Second Quarter 2026 ResultsMay 18, 2026 | businesswire.comFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 2 at 1:00 AM | Porter & Company (Ad)Cel-Sci: Fiscal Q2 Earnings SnapshotMay 15, 2026 | chron.comCEL-SCI Announces Closing of Public OfferingMay 13, 2026 | businesswire.comCEL-SCI Corporation Announces Pricing of Public OfferingMay 11, 2026 | businesswire.comCEL-SCI CorporationMay 5, 2026 | edition.cnn.comCEL-SCI Reports Fiscal First Quarter 2026 ResultsFebruary 18, 2026 | finance.yahoo.comSee More Headlines CVM Stock Analysis - Frequently Asked Questions How have CVM shares performed this year? Cel-Sci's stock was trading at $5.26 on January 1st, 2026. Since then, CVM stock has decreased by 71.7% and is now trading at $1.49. How were Cel-Sci's earnings last quarter? Cel-Sci Corporation (NYSEAMERICAN:CVM) released its quarterly earnings data on Friday, May, 15th. The company reported ($0.67) EPS for the quarter. When did Cel-Sci's stock split? Cel-Sci shares reverse split before market open on Thursday, June 15th 2017.The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Cel-Sci's major shareholders? Top institutional shareholders of Cel-Sci include Renaissance Technologies LLC (0.42%). Insiders that own company stock include Geert R Kersten, Patricia B Prichep and Robert Eugene Watson. View institutional ownership trends. How do I buy shares of Cel-Sci? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cel-Sci own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cel-Sci investors own include Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Savara (SVRA), Gilead Sciences (GILD) and Company Calendar Last Earnings5/15/2026Today6/02/2026Fiscal Year End9/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 CVM's financial health is in the Red zone, according to TradeSmith. CVM has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry N/A Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:CVM CIK725363 Webcel-sci.com Phone703-506-9460Fax703-506-9471Employees43Year Founded1983Profitability EPS (Trailing Twelve Months)($9.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-274.86% Return on Assets-126.47% Debt Debt-to-Equity Ratio0.64 Current Ratio0.60 Quick Ratio0.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book0.64Miscellaneous Outstanding Shares8,490,000Free Float7,299,000Market Cap$12.65 million OptionableOptionable Beta0.54 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSEAMERICAN:CVM) was last updated on 6/2/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredSecret behind near perfectly timed stock trades…?After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...Traders Agency | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredGold hit $4,500 - but these miners haven't caught up yet$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cel-Sci Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cel-Sci With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
